irinotecan has been researched along with Astrocytoma, Grade IV in 139 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.44) | 18.2507 |
| 2000's | 32 (23.02) | 29.6817 |
| 2010's | 90 (64.75) | 24.3611 |
| 2020's | 15 (10.79) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JP; Chuang, CC; Lan, YH; Lu, YJ; Weng, YL | 1 |
| Jangili, P; Kang, RH; Kim, D; Kim, JS; Park, YK; Zi, S | 1 |
| Ballester, LY; Bhattacharjee, MB; Brown, RE; Buja, LM; Chen, L; Glass, WF; Hergenroeder, GW; Hunter, RL; Linendoll, N; Lu, G; Pilichowska, M; Pillai, AK; Rao, M; Tian, X; Wu, JK; Zhang, R; Zhu, JJ; Zhu, P | 1 |
| Beige, A; Borsotti, F; Farah, W; Ghiringhelli, F; Ilie, SM; Lecuelle, J; Mazilu, I; Truc, G; Truntzer, C; Vincent, J | 1 |
| Cho, J; Cho, KR; Choi, JW; Koh, HK; Koh, YC; Lee, HS; Lim, SD; Park, JH; Yoon, SY | 1 |
| Abrey, LE; Aftab, DT; Cho, NS; Cloughesy, TF; Ellingson, BM; Garcia, J; Hagiwara, A; Harats, D; Hessel, C; Morris, CJ; Nathanson, DA; Oshima, S; Oughourlian, TC; Rachmilewitz Minei, T; Raymond, C; Sanvito, F; Telesca, D; Wen, PY | 1 |
| Mellinghoff, IK | 1 |
| Almond, L; Cruickshank, G; Daniel, S; Detta, A; Gawley, M; Hingtgen, S; Kaur, S; Lastakchi, S; McConville, C; Miller, R; Sheets, K | 1 |
| Ahn, DR; Huh, E; Jang, JE; Kang, JS; Kang, RH; Kang, SJ; Kim, D; Kim, HY; Oh, MS; Sailor, MJ; Yeo, SG | 1 |
| Chan, LY; Chen, JP; Chuang, CC; Hsu, PW; Lan, YH; Lu, WT; Lu, YJ | 1 |
| Fioretzaki, RG; Kosmas, C; Papageorgiou, GI; Tsakatikas, SA | 1 |
| Baekey, J; Carcieri, A; Cielo, D; Disano, D; Donnelly, J; Elinzano, H; MacKinnon, K; Mohler, A; Robison, J; Safran, H; Sturtevant, A; Toms, S; Vatketich, J; Wood, R | 1 |
| Chen, SM; Liu, SJ; Lo, WL; Tang, YL; Tseng, YY; Yang, TC | 1 |
| Ardakani, YH; Dinarvand, R; Rezaei, M; Shirazi, AS; Varshochian, R | 1 |
| Beberok, A; Maszczyk, M; Rok, J; Rzepka, Z; Wrześniok, D | 1 |
| He, Z; Jie, M; Li, HF; Lin, JM; Liu, H; Mao, S | 1 |
| DeLuca, JG; Herman, JA; Lee, E; Paddison, P; Pain, M; Toledo, CM; Wang, H; Yong, RL; Zhu, J | 1 |
| Belka, C; Friedrich, F; Glas, M; Goldbrunner, R; Grau, S; Grauer, O; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Krex, D; Leutgeb, B; Mack, F; Nießen, M; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Tabatabai, G; Tzaridis, T; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A | 1 |
| Bähr, O; Breuer, S; Burger, MC; Cieplik, HC; Franz, K; Harter, PN; Steinbach, JP | 1 |
| Neil, D | 1 |
| Bähr, O; Belka, C; Braun, C; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Kortmann, RD; Krex, D; Mack, F; Niessen, M; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Steinbach, JP; Stuplich, M; Tzaridis, T; Vatter, H; Weyerbrock, A | 1 |
| Abd El-Aty, AM; Cetin, M; Galateanu, B; Gundogdu, B; Hacimuftuoglu, A; Jeong, JH; Jung, TW; Mezhuev, Y; Mohammadzadeh, M; Nalci, KA; Okkay, U; Stivaktakis, P; Taghizadehghalehjoughi, A; Taspinar, M; Taspinar, N; Tsatsakis, A; Ugur, AB; Uyanik, A | 1 |
| Fastner, G; Greil, R; Huemer, F; Kleindienst, W; Machegger, L; Romagna, A; Schwartz, C; Weis, S; Weiss, L; Winkler, PA | 1 |
| Ameratunga, M; Grant, R; Khasraw, M; Pavlakis, N; Simes, J; Wheeler, H | 1 |
| Curran, WJ; Hartford, AC; Lieberman, FS; Mehta, MP; Robins, HI; Schultz, C; Smith, RP; Tsien, CI; Wang, M; Werner-Wasik, M; Zhang, P | 1 |
| Bobiak, S; Dastani, H; Kim Le, T; Korytowsky, B; Norden, AD; Singh, P; You, M | 1 |
| Anderson, CD; Burton, EC; Chakravarti, A; Chesnick, HM; King, PD; Lehman, NL; Li, X; McElroy, JP; Mifsud, CS; Sak, M; Usubalieva, A; Zumbar, CT | 1 |
| Bähr, O; Belka, C; Borchers, C; Galldiks, N; Gerlach, R; Glas, M; Goldbrunner, R; Hänel, M; Hattingen, E; Hau, P; Herrlinger, U; Junold, N; Kebir, S; Krex, D; Mack, F; Proescholdt, M; Rohde, V; Sabel, M; Schäfer, N; Schaub, C; Schlegel, U; Schmidt-Graf, F; Seidel, C; Steinbach, JP; Tabatabai, G; Tzaridis, T; Vatter, H; Weller, J; Weyerbrock, A | 1 |
| Banfi, R; Cecchi, M; Ceroti, M; Vaiani, M | 1 |
| Barboriak, DP; Bokstein, F; Boxerman, JL; Gilbert, MR; McKinstry, RC; Ratai, EM; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Bouakaz, A; Escoffre, JM; Lecomte, T; Novell, A; Serrière, S | 1 |
| Autran, D; Barrie, M; Boucard, C; Chinot, O; Loundou, A; Matta, M; Tabouret, E; Thiebaut, A | 1 |
| Barboriak, DP; Boxerman, JL; Chi, TL; Gilbert, MR; Jain, R; Larvie, M; Safriel, Y; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Blasius, E; Boström, J; Glas, M; Greschus, S; Herrlinger, U; Kebir, S; Landwehr, C; Mack, F; Rasch, K; Schäfer, N; Schaub, C; Scheffler, B; Seifert, M; Simon, M; Stuplich, M; Urbach, H; Vilz, B; Waha, A | 1 |
| Anghileri, E; Bertolini, F; Bruzzone, MG; Calleri, A; Ceroni, M; Cuppini, L; Di Stefano, AL; Eoli, M; Finocchiaro, G; Mancuso, P; Pellegatta, S; Porrati, P; Prodi, E | 1 |
| Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G | 1 |
| Abbasi, T; Bharati, IS; Chao, Y; Cong, X; Fogal, V; Gallagher, M; Jiang, P; Kesari, S; Makale, M; Mukthavaram, R; Mukthavavam, R; Nomura, N; Pastorino, S; Pingle, SC; Vali, S | 1 |
| Ask, A; Costa, JC; Engelholm, S; Grunnet, K; Hansen, S; Hofland, KF; Kristiansen, C; Lassen, U; Muhic, A; Poulsen, HS; Schultz, HP; Sorensen, M; Thomsen, C | 1 |
| Gemeinhart, RA; Köllmer, M; Liu, Y; Nitsche, LC; Sharma, V; Szymusiak, M | 1 |
| Anghileri, E; Aquino, D; Bruzzone, MG; Cuppini, L; Di Stefano, AL; Eoli, M; Finocchiaro, G; Scotti, A | 1 |
| Egle, A; Greil, R; Grundbichler, M; Hufnagl, C; Magnes, T; Melchardt, T; Moik, M; Strasser, M; Weiss, L | 1 |
| Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dalban, C; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Honnorat, J; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I | 1 |
| Boisselier, B; Chinot, O; Delattre, JY; Di Stefano, AL; Ducray, F; Farina, P; Figarella-Branger, D; Gallego Perez-Larraya, J; Honnorat, J; Idbaih, A; Laffaire, J; Marie, Y; Sanson, M; Vintonenko, N | 1 |
| Rovere, RK | 1 |
| Kjaer, A; Kristoffersen, K; Lassen, U; Madsen, J; Michaelsen, SR; Nedergaard, MK; Poulsen, HS; Stockhausen, MT | 1 |
| Corbacioglu, S; Debatin, KM; Engelke, J; Fulda, S; Halatsch, ME; Karpel-Massler, G; Nonnenmacher, L; Simmet, T; Westhoff, MA | 1 |
| Ameratunga, MS; Grant, R; Khasraw, M; Pavlakis, N; Wheeler, H | 1 |
| Alexandru-Abrams, D; Bota, DA; Hsu, FP; Paff, M | 1 |
| Barboriak, DP; Boxerman, JL; Gilbert, MR; Prah, M; Schmainda, KM; Snyder, BS; Sorensen, AG; Zhang, Z | 1 |
| Berman, J; Bradford, WD; Chen, G; Conkright, J; Haug, JS; Kucharavy, A; Li, R; McCroskey, S; Mulla, WA; Rubinstein, B; Seidel, CW; Tsai, HJ; Weems, L | 1 |
| Adachi, S; Arakawa, Y; Heike, T; Hiramatsu, H; Mizowaki, T; Nishiuchi, R; Saida, S; Shibata, H; Umeda, K; Watanabe, K | 1 |
| Gil-Ranedo, J; Mendiburu-Eliçabe, M | 1 |
| Beccaria, K; Carpentier, A; Farinotti, R; Fernandez, C; Goldwirt, L; Idbaih, A; Labussiere, M; Levasseur, C; Milane, A; Schmitt, C | 1 |
| Desjardins, A; Friedman, HS; Herndon, JE; Lipp, ES; Lou, E; McSherry, F; Miller, E; Peters, KB; Reardon, DA; Vredenburgh, JJ | 1 |
| Chang, TM; Kau, YC; Liu, SJ; Su, CH; Tseng, YY; Wang, YC; Yang, TC | 1 |
| Almeida, DS; Caeiro, C; Carvalho, BF; Castro, L; Costa, A; Damasceno, M; Fernandes, AC; Linhares, P; Osório, L; Sampaio, LV; Vaz, RC | 1 |
| Adamson, C; Agarwal, VJ; Babu, R; Britt, D; Friedman, AH; Grossi, PM; Iyer, A; Karikari, IO; Komisarow, JM; Rahimpour, S; Thomas, S | 1 |
| Abdel-Rahman, O; Fouad, M | 1 |
| Li, H; Li, X; Ni, S; Su, W; Wang, B; Wang, J; Xia, T; Yao, Q; Zhu, X | 1 |
| Anantha, M; Backstrom, I; Bally, MB; Chu, F; Kalra, J; Masin, D; Strutt, D; Verreault, M; Walker, D; Waterhouse, D; Wehbe, M; Yapp, DT | 1 |
| Balañá, C; Benavides, M; Fleitas, T; Gallego, O; Gil-Gil, M; Martínez-Sales, V; Palomero, I; Pérez-Segura, P; Reche, E; Reynés, G; Vaz, MA; Vila, V | 1 |
| Blumenthal, DT; Bokstein, F; Mendel, L | 1 |
| Broholm, H; Christensen, IJ; Dahlrot, RH; Grunnet, K; Hansen, S; Kosteljanetz, M; Larsen, VA; Lassen, U; Michaelsen, SR; Poulsen, HS; Toft, A; Urup, T | 1 |
| Belka, C; Brehmer, S; Dunkl, E; Fietkau, R; Friedrich, F; Gerlach, R; Glas, M; Goldbrunner, R; Grau, S; Hänel, M; Hau, P; Herrlinger, U; Kebir, S; Kohnen, R; Kortmann, RD; Krex, D; Leutgeb, B; Maciaczyk, J; Mack, F; Mayer-Steinacker, R; Mehdorn, M; Pietsch, T; Proescholdt, M; Ringel, F; Rohde, V; Ronellenfitsch, MW; Sabel, M; Schäfer, N; Schlegel, U; Schnell, O; Steinbach, JP; Stummer, W; Stuplich, M; Tüttenberg, J; Uhl, M; Urbach, H; Vajkoczy, P; Weyerbrock, A | 1 |
| Granovetter, M | 1 |
| Bähr, O; Banat, M; Filmann, N; Fimmers, R; Franz, K; Glas, M; Herrlinger, U; Kebir, S; Mack, F; Mittelbronn, M; Rieger, J; Schäfer, N; Schaub, C; Steinbach, JP; Thiepold, AL; Tichy, J; Waha, A | 1 |
| Anota, A; Bonnetain, F; Campello, C; Castera, D; Chauffert, B; Chinot, O; Dabakuyo, S; Dalban, C; Ducray, F; Durando, X; Fabbro, M; Feuvret, L; Frappaz, D; Frenay, M; Ghiringhelli, F; Guillamo, JS; Paquette, B; Schott, R; Skrzypski, J; Taillandier, L; Taillia, H; Tennevet, I; Vernerey, D | 1 |
| Astorgues-Xerri, L; Bekradda, M; Berenguer-Daizé, C; Cayol, M; Cvitkovic, E; Lokiec, F; MacKenzie, S; Noel, K; Odore, E; Ouafik, L; Rezai, K; Riveiro, ME | 1 |
| Huang, YC; Lee, WH; Liu, SC; Liu, SJ; Su, CH; Tseng, YY; Wang, YC; Yang, ST | 1 |
| Boongird, A; Chaimongkolnukul, K; Hongeng, S; Kengkoom, K; Manaspon, C; Nasongkla, N; Nittayacharn, P; Vejjasilpa, K | 1 |
| Abrey, LE; Aftab, DT; Cloughesy, TF; Ellingson, BM; Harris, RJ; Hessel, C; Lai, A; Leu, K; Mason, WP; Nghiemphu, PL; Pope, WB; Sahebjam, S; Schwab, GM; Wen, PY; Woodworth, DC; Zaw, O | 1 |
| Cole, BF; Eskey, CJ; Fadul, CE; Kingman, LS; Meyer, LP; Newton, HB; Pipas, JM; Rhodes, CH; Roberts, DW | 1 |
| Ahmad, A; Ali, SA; Bejjani, G; Braffet, M; Friedland, DM; McHayleh, WM; Rahman, M; Sehgal, R | 1 |
| Buie, LW; Valgus, J | 1 |
| Delattre, JY; Omuro, AM | 1 |
| Albert, PS; Butman, JA; Camphausen, K; Duic, P; Fine, HA; Garren, N; Kim, L; Kreisl, TN; Mackey, M; Moore, K; Park, J; Royce, C; Stroud, I | 1 |
| Dehais, C; Laigle-Donadey, F; Mazeron, JJ; Sanson, M | 1 |
| Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Abrey, LE; Cloughesy, T; Friedman, HS; Huang, J; Jensen, R; Mikkelsen, T; Nicholas, MK; Paleologos, N; Prados, MD; Schiff, D; Vredenburgh, J; Wen, PY; Yung, WK; Zheng, M | 1 |
| Baltas, D; Chatzisotiriou, A; Fountzilas, G; Fragkoulidi, A; Iliadis, G; Kalogera-Fountzila, A; Misailidou, D; Selviaridis, P; Tselis, N; Zamboglou, N | 1 |
| Batchelor, TT; Frosch, MP; Gerstner, ER | 1 |
| Ames, MM; Arusell, R; Ballman, KV; Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Hammack, JE; Jaeckle, KA; McGovern, RM; Morton, RF; Nikcevich, DA; Reid, JM; Safgren, SL; Schomberg, PJ; Uhm, JH; Wender, DB | 1 |
| Kenmotsu, H; Koga, Y; Kuratsu, J; Kuroda, J; Matsumura, Y; Sugino, T; Yasunaga, M | 1 |
| Chinnaiyan, P; Kahali, S; Sarcar, B | 1 |
| Broholm, H; Hansen, S; Hasselbalch, B; Holmberg, M; Kosteljanetz, M; Lassen, U; Poulsen, HS; Stockhausen, MT; Sørensen, M | 1 |
| Broholm, H; Christensen, IJ; Eriksen, JG; Grunnet, K; Hasselbalch, B; Horsman, MR; Lassen, U; Poulsen, HS; Stockhausen, MT | 1 |
| Gizewski, ER; Lanzman, RS; Mathys, C; Mödder, U; Rapp, M; Ringelstein, A; Sabel, M; Saleh, A; Schroeteler, J; Turowski, B | 1 |
| Dosa, E; Kraemer, DF; Neuwelt, EA; Thompson, EM | 1 |
| Almubarak, M; Altaha, R; Khan, M; Nagaiah, G | 1 |
| Bailey, L; Desjardins, A; Friedman, A; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, J; Threatt, S; Vredenburgh, JJ | 1 |
| Dalla Palma, M; Farina, P; Furini, L; Lombardi, G; Manara, R; Nicoletto, O; Pastorelli, D; Rotilio, A; Zagonel, V; Zustovich, F | 1 |
| Barboriak, DP; Desjardins, A; Friedman, HS; Paldino, MJ; Vredenburgh, JJ | 1 |
| Callot, V; Chinot, O; Cozzone, PJ; Fellah, S; Girard, N | 1 |
| Brown, MS; Cloughesy, T; Das, A; Goldin, J; Hambleton, J; Huo, J; Kim, HJ; Paton, VE; Pope, WB; Xia, Q | 1 |
| Hasselbalch, B; Jakobsen, JN; Lassen, U; Poulsen, HS; Stockhausen, MT | 1 |
| Anantha, M; Bally, MB; Kozlowski, P; Masin, D; Strutt, D; Verreault, M; Waterhouse, D; Yapp, DT; Yung, A | 1 |
| Dehais, C; Delattre, JY; Golmard, JL; Jouniaux-Delbez, N; Liou, A; Nguyen, BK; Souvannavong, V; Tadrist, C | 1 |
| Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Kirkpatrick, JP; Marcello, J; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Coan, A; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Chan, RT; Fung, CF; Hung, KN; Leung, GK; Ng, GK; Pu, JK | 1 |
| Cheema, TA; Kanai, R; Kim, GW; Martuza, RL; Passer, B; Rabkin, SD; Wakimoto, H | 1 |
| Bulusu, A; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Peters, KB; Reardon, DA; Sampson, JH; Threatt, S; Vredenburgh, JJ | 1 |
| Anantha, M; Bally, MB; Masin, D; Strutt, D; Verreault, M; Waterhouse, D; Yapp, DT | 1 |
| Fourcade, S; Gaudy-Marqueste, C; Grob, JJ; Richard, MA; Tasei, AM | 1 |
| Brem, S; Chinnaiyan, P; Chowdhary, S; Kahali, S; Murtagh, R; Pan, E; Potthast, L; Prabhu, A; Rojiani, A; Sarcar, B; Tsai, YY; Yu, HM | 1 |
| Audrain, O; Carsin, B; Gedouin, D; Hamlat, A; Lecouillard, I; Lesimple, T; Louvel, G; Mesbah, H; Quillien, V; Riffaud, L; Vauleon, E | 1 |
| Delattre, JY; Gállego Pérez-Larraya, J; González-Aguilar, A; Guillevin, R; Hoang-Xuan, K; Houillier, C; Lahutte, M; Petrirena, G; Reyes-Botero, G; Sanson, M | 1 |
| Bellanger, A; Hassani, L; Hassani, Y; Hochart, C; Taillibert, S; Xuan, KH | 1 |
| Grunnet, K; Hansen, S; Holmberg, M; Lassen, U; Møller, S; Poulsen, HS; Schultz, H; Sorensen, M | 1 |
| Boongird, A; Hongeng, S; Manaspon, C; Nasongkla, N | 1 |
| Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R | 1 |
| Huang, S; Wang, Z; Zhang, G | 1 |
| Bankiewicz, K; Berger, MS; Butowski, N; Chen, PY; Drummond, DC; Fitzgerald, JB; Forsayeth, JR; James, CD; Kalra, A; Kirpotin, DB; Ozawa, T; Prados, MD; Wei, KC | 1 |
| Armand, JP; Boige, V; Fabbro, M; Faivre, S; Frenay, M; Germa, C; Raymond, E; Rixe, O; Rodier, JM; Sicard, E; Vassal, G; Vernillet, L | 1 |
| Ames, M; Buckner, JC; Cha, S; Erlichman, C; Kaufmann, SH; Miller, LL; O'Fallon, JR; Reid, JM; Schaaf, LJ; Wright, K | 1 |
| Chen, TC; Fry, D; Liebes, L; Su, S | 1 |
| Bamberg, M; Belka, C; Jendrossek, V | 1 |
| Cloughesy, TF; Liau, LM; Mischel, PS; Wang, Y; Zhu, S | 1 |
| Lobrinus, JA; Matzinger, O; Michielin, O; Périard, D; Stupp, R; Udry, E | 1 |
| Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K | 1 |
| Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K | 1 |
| Amistà, P; Basso, U; Brandes, AA; Ermani, M; Monfardini, S; Nicolardi, L; Reni, M; Sotti, G; Tosoni, A; Valduga, F | 1 |
| Bouzourene, H; Chaubert, P; Sandmeier, D | 1 |
| Bernshausen, A; Bieler, A; Dravits, T; Gansbacher, B; Glockzin, G; Holm, PS; Köhler-Vargas, N; Lage, H; Mantwill, K | 1 |
| Alemany, R; Alonso, MM; Bekele, BN; Curiel, DT; Fueyo, J; Gomez-Manzano, C; Jiang, H; Lang, FF; McCormick, F; Yung, WK; Zhou, X | 1 |
| Hunter, K; Jones-Bolin, S; Klein-Szanto, A; Ruggeri, B; Zhao, H | 1 |
| Chen, TC; Hofman, FM; Lee, AS; Pyrko, P; Schönthal, AH | 1 |
| Brem, S; Wong, ET | 1 |
| Bailey, L; Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; Quinn, JA; Reardon, DA; Rich, JN; Sampson, J; Sathornsumetee, S; Vredenburgh, JJ; Wagner, M | 1 |
| Chamberlain, MC | 2 |
| Colman, H; Conrad, CA; de Groot, JF; Giglio, P; Gilbert, MR; Groves, MD; Hess, KR; Hsu, SH; Ictech, SE; Jackson, EF; Levin, VA; Mahankali, S; Puduvalli, VK; Ritterhouse, MG; Yung, WK | 1 |
| Feun, L; Savaraj, N | 1 |
| Barnett, GH; Kaakaji, R; Kikuchi, H; Kondo, S; Kondo, Y; Morimura, T; Nakatsu, S; Peterson, JW; Takeuchi, J; Yin, D | 1 |
| Ashley, D; Bigner, DD; Cloughsey, T; Cokgor, I; Colvin, OM; Elfring, GL; Friedman, AH; Friedman, HS; Haglund, M; Houghton, PJ; Kerby, T; Lawyer, J; Lovell, S; Malczyn, J; McLendon, RE; Miller, LL; Parry, M; Petros, WP; Provenzale, JM; Rasheed, K; Rich, J; Schaaf, LJ; Stewart, ES | 1 |
| Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M | 1 |
| Burger, RA; Danks, MK; Harris, LC; Iyengar, RV; Krull, EJ; Pawlik, CA; Phelps, DA; Potter, PM | 1 |
| Beason, R; Bottom, K; Eastwood, J; Friedman, AH; Friedman, HS; Gururangan, S; McLendon, RE; Miller, LL; Tourt-Uhlig, S; Turner, CD; Watral, M | 1 |
12 review(s) available for irinotecan and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Anti-angiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Progression-Free Survival; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2018 |
Antiangiogenic therapy for high-grade glioma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Hypertension; Irinotecan; Lomustine; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Proteinuria; Randomized Controlled Trials as Topic; Snake Venoms; Temozolomide | 2014 |
The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cancer Vaccines; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; ErbB Receptors; Glioblastoma; Humans; Immunotherapy; Irinotecan; Mice; Temozolomide; Vaccination; Vaccines, Subunit | 2014 |
Irinotecan-based regimens for recurrent glioblastoma multiforme: [corrected] a systematic review.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Glioblastoma; Humans; Irinotecan; Prospective Studies; Salvage Therapy; Survival Analysis | 2015 |
Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; Disease-Free Survival; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Vascular Endothelial Growth Factor A | 2008 |
[Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Dacarbazine; Glioblastoma; Humans; Irinotecan; Neovascularization, Pathologic; Temozolomide; Vascular Endothelial Growth Factor A | 2009 |
Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carmustine; Drug Implants; Female; Glioblastoma; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oligodendroglioma | 2010 |
Irinotecan and bevacizumab in recurrent glioblastoma multiforme.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Middle Aged; Recurrence; Survival Analysis | 2011 |
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Disease Progression; Drug Approval; Europe; Glioblastoma; Humans; Hungary; Irinotecan; Magnetic Resonance Imaging; Off-Label Use; Recurrence; Temozolomide; Treatment Outcome | 2012 |
A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult | 2012 |
Novel chemotherapeutic agents for the treatment of glioblastoma multiforme.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Camptothecin; Cell Differentiation; Dacarbazine; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Glioblastoma; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Signal Transduction; Temozolomide | 2003 |
Topoisomerase I inhibitors for the treatment of brain tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2008 |
40 trial(s) available for irinotecan and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Nanoliposomal Irinotecan and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: BrUOG329, A Phase I Brown University Oncology Research Group Trial.
Topics: Administration, Metronomic; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Diarrhea; Drug Delivery Systems; Female; Glioblastoma; Humans; Irinotecan; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Nanostructures; Neutropenia; Temozolomide | 2021 |
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Quality of Life; Survival Rate; Temozolomide; Tumor Suppressor Proteins | 2018 |
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Growth Processes; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Radiotherapy; Temozolomide; Tumor Suppressor Proteins | 2018 |
Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.
Topics: Adolescent; Adult; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Safety; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2019 |
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Survival Rate; Temozolomide | 2019 |
Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Choline; Creatine; Dacarbazine; Feasibility Studies; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prognosis; Prospective Studies; Survival Rate; Temozolomide | 2013 |
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Contrast Media; Dacarbazine; Female; Follow-Up Studies; Glioblastoma; Humans; Imaging, Three-Dimensional; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate; Temozolomide; Young Adult | 2013 |
A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2014 |
Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Temozolomide; Treatment Outcome | 2014 |
Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Temozolomide | 2014 |
An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligonucleotide Array Sequence Analysis; Retrospective Studies; Transcriptome | 2014 |
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Cortex; Contrast Media; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Temozolomide; Treatment Outcome; Young Adult | 2015 |
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Temozolomide; Treatment Outcome | 2015 |
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2016 |
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Promoter Regions, Genetic; Temozolomide; Tumor Suppressor Proteins | 2016 |
Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Prognosis; Psychometrics; Quality of Life; Temozolomide | 2016 |
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Contrast Media; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Molecular Imaging; Necrosis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Immunosuppressive Agents; Irinotecan; Male; Middle Aged; Survival Analysis; Thalidomide | 2008 |
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2008 |
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged | 2009 |
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Survival Rate; Temozolomide; Treatment Outcome | 2009 |
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Drug Administration Schedule; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Young Adult | 2009 |
Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Camptothecin; Carmustine; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Radiotherapy; Statistics as Topic; Time Factors; Young Adult | 2010 |
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cetuximab; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Temozolomide; Young Adult | 2010 |
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Craniotomy; Dacarbazine; Dexamethasone; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Glioblastoma; Glucocorticoids; Humans; Injections, Intravenous; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide; Tumor Burden; Young Adult | 2012 |
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local | 2011 |
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Prognosis; Radiotherapy; Survival Analysis; Temozolomide; Treatment Outcome; Young Adult | 2011 |
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local | 2011 |
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2012 |
Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Hydroxamic Acids; Insulin-Like Growth Factor Binding Protein 5; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Proteomics; Vorinostat | 2012 |
A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Standard of Care; Survival Rate; Young Adult | 2012 |
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Glioblastoma; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Treatment Outcome; Vomiting | 2003 |
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; Confidence Intervals; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Oligodendroglioma | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 2004 |
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carmustine; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Electroencephalography; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Salvage Therapy; Survival Analysis; Temozolomide; Treatment Outcome | 2004 |
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate | 2007 |
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Thalidomide | 2008 |
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 1999 |
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Ependymoma; Female; Glioblastoma; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Medulloblastoma; Topoisomerase Inhibitors | 2002 |
Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Salvage Therapy; Supratentorial Neoplasms; Thrombocytopenia | 2002 |
87 other study(ies) available for irinotecan and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Targeted delivery of irinotecan and SLP2 shRNA with GRP-conjugated magnetic graphene oxide for glioblastoma treatment.
Topics: Animals; Cell Line, Tumor; DNA; Drug Delivery Systems; Gastrin-Releasing Peptide; Glioblastoma; Graphite; Irinotecan; Ligands; Magnesium Oxide; Magnetic Phenomena; Mice; Mice, Nude; RNA, Small Interfering | 2022 |
SIWV tetrapeptide and ROS-responsive prodrug conjugate for advanced glioblastoma therapy.
Topics: Cell Line, Tumor; Glioblastoma; Humans; Irinotecan; Prodrugs; Reactive Oxygen Species | 2022 |
Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Glioblastoma; Glioma; Humans; Irinotecan; Neoplasm Recurrence, Local; Pneumonia, Aspiration; Temozolomide | 2022 |
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study.
Topics: Bevacizumab; Chronic Disease; Cytotoxins; Glioblastoma; Humans; Irinotecan; Recurrence; Retrospective Studies; Temozolomide | 2022 |
Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors.
Topics: Bevacizumab; Glioblastoma; Humans; Irinotecan; Progression-Free Survival; Retrospective Studies | 2022 |
Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
Topics: Angiogenesis Inhibitors; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Neoplasm Recurrence, Local | 2023 |
Flashback Foreword: Bevacizumab and Irinotecan in Recurrent Glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local | 2023 |
Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Glioblastoma; Humans; Irinotecan; Mice; Pharmaceutical Preparations; Temozolomide | 2020 |
A brain tumor-homing tetra-peptide delivers a nano-therapeutic for more effective treatment of a mouse model of glioblastoma.
Topics: Animals; Annexin A3; Antineoplastic Agents; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Carriers; Female; Glioblastoma; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Oligopeptides; Peptide Fragments; Polyethylene Glycols; Silicon; Xenograft Model Antitumor Assays | 2020 |
Injectable Thermo-Sensitive Chitosan Hydrogel Containing CPT-11-Loaded EGFR-Targeted Graphene Oxide and SLP2 shRNA for Localized Drug/Gene Delivery in Glioblastoma Therapy.
Topics: Blood Proteins; Cell Line, Tumor; Chitosan; Drug Delivery Systems; ErbB Receptors; Gene Transfer Techniques; Glioblastoma; Graphite; Humans; Hydrogels; Irinotecan; Membrane Proteins; Neoplasm Proteins; RNA, Small Interfering | 2020 |
Notable response of a young adult with recurrent glioblastoma multiforme to vincristine-irinotecan-temozolomide and bevacizumab.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Disease-Free Survival; Glioblastoma; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Prognosis; Temozolomide; Vincristine | 2021 |
Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Irinotecan; Mice; Microplastics; Microscopy, Electron, Scanning; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2021 |
SN38 loaded nanostructured lipid carriers (NLCs); preparation and in vitro evaluations against glioblastoma.
Topics: Calorimetry, Differential Scanning; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Screening Assays, Antitumor; Excipients; Glioblastoma; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Irinotecan; Lipids; Microscopy, Confocal; Nanoparticles; Nanostructures; Particle Size; Solubility; Solvents; Tetrazolium Salts; Thiazoles | 2021 |
Neobavaisoflavone May Modulate the Activity of Topoisomerase Inhibitors towards U-87 MG Cells: An In Vitro Study.
Topics: Antibiotics, Antineoplastic; Astrocytes; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Etoposide; Glioblastoma; Glutathione; Humans; Irinotecan; Isoflavones; Plant Extracts; Psoralea; Signal Transduction; Topoisomerase II Inhibitors | 2021 |
Evaluation of drug combination for glioblastoma based on an intestine-liver metabolic model on microchip.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Caco-2 Cells; Coculture Techniques; Cyclophosphamide; Dacarbazine; Drug Combinations; Drug Delivery Systems; Glioblastoma; Hep G2 Cells; Humans; Intestinal Absorption; Intestines; Irinotecan; Liver; Models, Biological | 2017 |
Sensitivity to
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Cell Cycle Proteins; Cell Line, Tumor; Etoposide; Gene Expression Profiling; Glioblastoma; Humans; Irinotecan; Protein Serine-Threonine Kinases; RNA, Messenger | 2017 |
Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local | 2017 |
Letter to the Editor. Puzzling posology: was the bevacizumab regimen in recurrent glioblastoma misreported?
Topics: Angiogenesis Inhibitors; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local | 2018 |
Effect of metformin/irinotecan-loaded poly-lactic-co-glycolic acid nanoparticles on glioblastoma: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Glioblastoma; Humans; Irinotecan; Metformin; Microscopy, Electron, Transmission; Nanoparticles; Neoplasms, Experimental; Neurons; Polylactic Acid-Polyglycolic Acid Copolymer; Rats | 2018 |
Extensive Leptomeningeal Intracranial and Spinal Metastases in a Patient with a Supratentorial Glioblastoma Multiforme, IDH-Wildtype.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy, Adjuvant; DNA Mutational Analysis; Glioblastoma; High-Throughput Nucleotide Sequencing; Humans; Irinotecan; Isocitrate Dehydrogenase; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Microsatellite Instability; Middle Aged; Neurosurgical Procedures; Palliative Care; Radiotherapy; Sequence Analysis, DNA; Supratentorial Neoplasms; Temozolomide | 2018 |
A Real-World Claims Analysis of Costs and Patterns of Care in Treated Patients with Glioblastoma Multiforme in the United States.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cost of Illness; Databases, Factual; Female; Glioblastoma; Health Care Costs; Hospitalization; Humans; Irinotecan; Lomustine; Male; Middle Aged; Prognosis; Retrospective Studies; Temozolomide; Time Factors; United States; Young Adult | 2019 |
Cytotoxic synergy between alisertib and carboplatin versus alisertib and irinotecan are inversely dependent on MGMT levels in glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Carboplatin; DNA Modification Methylases; DNA Repair Enzymes; Drug Synergism; Glioblastoma; Humans; Irinotecan; Pyrimidines; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2019 |
A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease-Free Survival; Glioblastoma; Humans; Irinotecan; Italy; Male; Middle Aged; Neoplasm Recurrence, Local; Off-Label Use; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Irinotecan delivery by microbubble-assisted ultrasound: in vitro validation and a pilot preclinical study.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Glioblastoma; Humans; Irinotecan; Male; Mice, Nude; Microbubbles; Ultrasonics | 2013 |
Limited impact of prognostic factors in patients with recurrent glioblastoma multiforme treated with a bevacizumab-based regimen.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioblastoma; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Steroids; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Topics: Adult; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Female; Germany; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Disease Progression; Endothelial Cells; Female; Glioblastoma; GPI-Linked Proteins; Humans; Immunophenotyping; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Prognosis; Treatment Outcome; Young Adult | 2013 |
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Disease-Free Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Approval; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplastic Stem Cells; Quinolines; Spheroids, Cellular; United States; United States Food and Drug Administration; Xenograft Model Antitumor Assays | 2014 |
Toroidal-spiral particles for codelivery of anti-VEGFR-2 antibody and irinotecan: a potential implant to hinder recurrence of glioblastoma multiforme.
Topics: Antibodies, Anti-Idiotypic; Camptothecin; Drug Delivery Systems; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Irinotecan; Particle Size; Polymers; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Parametric response maps of perfusion MRI may identify recurrent glioblastomas responsive to bevacizumab and irinotecan.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Perfusion Imaging; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Camptothecin; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Dacarbazine; Disease Progression; Drugs, Chinese Herbal; Female; Glioblastoma; Herb-Drug Interactions; Humans; Irinotecan; Liver; Middle Aged; Phytotherapy; Temozolomide | 2014 |
Bevacizumab as secondline treatment of glioblastoma - worth the effort?
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Dacarbazine; Glioblastoma; Humans; Irinotecan; Middle Aged; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide; Vascular Endothelial Growth Factor A | 2014 |
The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Female; Glioblastoma; Heterografts; Humans; Irinotecan; Mice, Nude; Neuroimaging; Positron-Emission Tomography; Tyrosine | 2014 |
RIST: a potent new combination therapy for glioblastoma.
Topics: Adolescent; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Child; Dacarbazine; Female; Glioblastoma; Humans; Indoles; Irinotecan; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Xenograft Model Antitumor Assays | 2015 |
Targeting the adaptability of heterogeneous aneuploids.
Topics: Aneuploidy; Antifungal Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Candida albicans; Cell Line, Tumor; Drug Resistance, Fungal; Drug Resistance, Neoplasm; ErbB Receptors; Fluconazole; Glioblastoma; Humans; Hygromycin B; Irinotecan; Saccharomyces cerevisiae | 2015 |
Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Child, Preschool; Drug Therapy, Combination; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Prodrugs; Time Factors; Tomography, X-Ray Computed | 2015 |
Combination Therapy of Intraperitoneal Rapamycin and Convection- Enhanced Delivery of Nanoliposomal CPT-11 in Rodent Orthotopic Brain Tumor Xenografts.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Drug Monitoring; Glioblastoma; Humans; Infusions, Parenteral; Irinotecan; Liposomes; Rats; Sirolimus; Topoisomerase I Inhibitors; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Tissue Distribution | 2015 |
Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: In vitro and in vivo studies.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Camptothecin; Carmustine; Cisplatin; Glioblastoma; In Vitro Techniques; Irinotecan; Nanofibers; Rats; Rats, Wistar | 2015 |
Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies; Female; Glioblastoma; Humans; Irinotecan; Lomustine; Male; Middle Aged; Neoplasm Recurrence, Local; Portugal; Prevalence; Procarbazine; Retrospective Studies; Risk Assessment; Survival Analysis; Survival Rate; Treatment Outcome; Vincristine | 2015 |
Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Neurosurgical Procedures; Prognosis; Survival Analysis; Temozolomide | 2016 |
Anti-Neoplastic Cytotoxicity of SN-38-Loaded PCL/Gelatin Electrospun Composite Nanofiber Scaffolds against Human Glioblastoma Cells In Vitro.
Topics: Antineoplastic Agents; Biocompatible Materials; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Drug Liberation; Gelatin; Glioblastoma; Humans; Irinotecan; Membranes; Nanofibers; Polyesters; Tissue Engineering; Tissue Scaffolds | 2015 |
Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Dacarbazine; Drug Administration Schedule; Drug Compounding; Glioblastoma; Humans; Irinotecan; Liposomes; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Temozolomide; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The optimal regimen of bevacizumab for recurrent glioblastoma: does dose matter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Cyclophosphamide; Dacarbazine; Glioblastoma; Humans; Irinotecan; Lomustine; Neoplasm Grading; Neoplasm Recurrence, Local; Oligodendroglioma; Procarbazine; Radiotherapy; Singapore; Temozolomide; Teniposide; Vincristine | 2015 |
Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Models, Biological; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Young Adult | 2016 |
Potential treatment for a subtype of glioblastoma tumours.
Topics: Bevacizumab; Camptothecin; Disease-Free Survival; Glioblastoma; Humans; Irinotecan; Randomized Controlled Trials as Topic | 2016 |
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Drug Therapy, Combination; Female; Glioblastoma; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Topics: Acetanilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Everolimus; Gene Expression Regulation, Neoplastic; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Irinotecan; Mice; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
Advanced interstitial chemotherapy combined with targeted treatment of malignant glioma in rats by using drug-loaded nanofibrous membranes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Brain; Brain Neoplasms; Camptothecin; Cisplatin; Disease Models, Animal; Drug Delivery Systems; Ethylnitrosourea; Glioblastoma; Glioma; Humans; Irinotecan; Lactic Acid; Male; Nanofibers; Neurosurgical Procedures; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Tumor Burden | 2016 |
Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Cell Culture Techniques; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Delivery Systems; Drug Liberation; Female; Glioblastoma; Heterografts; Humans; Injections; Irinotecan; Mice, Inbred BALB C; Mice, Nude; Polyesters; Polyethylene Glycols | 2016 |
What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Glioblastoma; Glioma; Humans; Irinotecan | 2008 |
The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Chemotherapy, Adjuvant; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Models, Theoretical; Radiosurgery; Regression Analysis; Statistics as Topic; Temozolomide; Tumor Burden | 2009 |
Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diffusion Magnetic Resonance Imaging; Glioblastoma; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Young Adult | 2010 |
Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Glioblastoma; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Polymers; Xenograft Model Antitumor Assays | 2010 |
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Camptothecin; Cell Proliferation; Comet Assay; DNA Damage; DNA Repair; DNA Topoisomerases, Type I; Drug Synergism; Fluorescent Antibody Technique; Glioblastoma; Humans; Hydroxamic Acids; Irinotecan; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vorinostat | 2010 |
Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Brain Neoplasms; Camptothecin; Cell Hypoxia; Cetuximab; Drug Therapy, Combination; ErbB Receptors; Female; Glioblastoma; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prospective Studies | 2010 |
[Evaluation of ADC mapping as an early predictor for tumor response to chemotherapy in recurrent glioma treated with bevacizumab/irinotecan: proof of principle].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain; Brain Neoplasms; Camptothecin; Contrast Media; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Gadolinium; Glioblastoma; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Irinotecan; Male; Neoplasm Recurrence, Local; Sensitivity and Specificity; Vascular Endothelial Growth Factor A | 2010 |
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Dacarbazine; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Temozolomide | 2011 |
Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease-Free Survival; Glioblastoma; Humans; Irinotecan; Retrospective Studies; Treatment Outcome | 2010 |
A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Anisotropy; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Diffusion Tensor Imaging; Female; Glioblastoma; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis | 2012 |
Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Fatal Outcome; Glioblastoma; Humans; Irinotecan; Magnetic Resonance Angiography; Male; Neoplasm Recurrence, Local; Spin Labels | 2011 |
Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Capillary Permeability; Cell Line, Tumor; Chemistry, Pharmaceutical; DNA-Binding Proteins; Doxorubicin; Glioblastoma; Humans; Injections, Intravenous; Irinotecan; Liposomes; Mice; Mice, Knockout; Nanoparticles; Tumor Burden; Vincristine; Xenograft Model Antitumor Assays | 2011 |
[An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diagnostic Self Evaluation; Fatigue; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Recurrence; Surveys and Questionnaires | 2011 |
Using bevacizumab in the fight against malignant glioma: first results in Asian patients.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asian People; Bevacizumab; Brain Neoplasms; Camptothecin; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2011 |
Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Brain Neoplasms; Camptothecin; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Etoposide; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neural Stem Cells; Oncolytic Virotherapy; Oncolytic Viruses; Simplexvirus; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2011 |
Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Female; Glioblastoma; Humans; Irinotecan; Liposomes; Mice; Nanoparticles; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Localized skin necrosis of steroid-induced striae distensae: an unusual complication of bevacizumab and irinotecan therapy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Camptothecin; Chemoradiotherapy; Fatal Outcome; Glioblastoma; Humans; Irinotecan; Male; Methylprednisolone Hemisuccinate; Necrosis; Skin; Striae Distensae | 2011 |
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carmustine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cohort Studies; Dacarbazine; Drug Therapy, Combination; Glioblastoma; Humans; Irinotecan; Lomustine; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Radiation-Sensitizing Agents; Retrospective Studies; Temozolomide | 2012 |
Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Diagnostic Imaging; Disease Progression; Female; Glioblastoma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
[Monitoring and evaluation tools for irinotecan and bevacizumab in glioblastoma: from prescription to patient's information].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Contraindications; Drug Monitoring; Family; France; General Practice; Glioblastoma; Humans; Irinotecan; Medical Oncology; Off-Label Use; Pamphlets; Patient Education as Topic; Pharmaceutical Services; Pharmacovigilance; Prescription Drugs | 2012 |
Preparation and in vitro characterization of SN-38-loaded, self-forming polymeric depots as an injectable drug delivery system.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Caproates; Cell Line, Tumor; Drug Delivery Systems; Drug Stability; Glioblastoma; Humans; Irinotecan; Kinetics; Lactones; Polyesters; Polyethylene Glycols; Polymers | 2012 |
Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Convection; Drug Administration Routes; Drug Delivery Systems; Female; Glioblastoma; History, Ancient; Humans; Immunoenzyme Techniques; Injections, Intraperitoneal; Irinotecan; Liposomes; Mice; Mice, Nude; Nanoparticles; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group.
Topics: Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Glioblastoma; Glioma; Humans; Irinotecan | 2003 |
Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Topics: Anthracenes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Brain Neoplasms; Camptothecin; Cell Line; Glioblastoma; Humans; Irinotecan; Naphthalenes; Perylene; Protein Kinase C; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Staurosporine; Tamoxifen; Tumor Cells, Cultured | 2003 |
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cellular Senescence; DNA Damage; Enzyme Inhibitors; Exons; Gene Deletion; Glioblastoma; Humans; Irinotecan; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2004 |
Irinotecan-induced interstitial pneumonia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Dacarbazine; Diagnosis, Differential; Frontal Lobe; Glioblastoma; Humans; Irinotecan; Lung Diseases, Interstitial; Male; Radiography; Temozolomide | 2004 |
Irinotecan-induced colitis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers; Biopsy; Brain Neoplasms; Camptothecin; Colitis; Colon; Diarrhea; Glioblastoma; Humans; Ileum; Immunoenzyme Techniques; Irinotecan; Male; Topoisomerase I Inhibitors | 2005 |
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Blotting, Southern; Brain Neoplasms; Camptothecin; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Enzyme Inhibitors; Fibroblasts; Gene Deletion; Gene Expression; Gentian Violet; Glioblastoma; HeLa Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunohistochemistry; Irinotecan; Oncolytic Viruses; Protein Synthesis Inhibitors; Receptors, Virus; Tumor Cells, Cultured | 2006 |
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Brain Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Drug Synergism; Flow Cytometry; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; S Phase; Survival Rate; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma; Colonic Neoplasms; Dacarbazine; Glioblastoma; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Metastasis; Receptors, Vascular Endothelial Growth Factor; Temozolomide; Xenograft Model Antitumor Assays | 2006 |
The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Caspase 7; Catechin; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Fluorouracil; Glioblastoma; Heat-Shock Proteins; Humans; Irinotecan; Molecular Chaperones; RNA, Small Interfering; Temozolomide; Transcription Factor CHOP; Transfection | 2007 |
Taming glioblastoma: targeting angiogenesis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Prognosis; Survival Rate | 2007 |
Bevacizumab plus irinotecan in recurrent glioblastoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Disease Progression; Glioblastoma; Humans; Irinotecan; Neoplasm Recurrence, Local | 2008 |
Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Flow Cytometry; Glioblastoma; Humans; Irinotecan; Kinetics; Tumor Cells, Cultured | 1997 |
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Brain Neoplasms; Camptothecin; Dacarbazine; DNA Repair; Female; Glioblastoma; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Rhabdomyosarcoma; Temozolomide; Time Factors | 2000 |
Use of a modified ornithine decarboxylase promoter to achieve efficient c-MYC- or N-MYC-regulated protein expression.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Camptothecin; Carboxylesterase; Carboxylic Ester Hydrolases; Chloramphenicol O-Acetyltransferase; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Genes, myc; Genes, Reporter; Glioblastoma; Humans; Immunoblotting; Irinotecan; MyoD Protein; Neuroblastoma; Ornithine Decarboxylase; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Rabbits; Rhabdomyosarcoma; Transfection; Transgenes; Tumor Cells, Cultured | 2001 |